<DOC>
	<DOCNO>NCT00514345</DOCNO>
	<brief_summary>RATIONALE : Studying gene express sample blood young patient cancer treat ifosfamide may help doctor identify risk factor kidney damage . PURPOSE : This clinical trial look CYP3A5 gene see gene may risk factor kidney damage young patient cancer treat ifosfamide .</brief_summary>
	<brief_title>CYP3A5 Gene Risk Factor Kidney Damage Young Patients With Cancer Treated With Ifosfamide</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine CYP3A5 genotype young patient cancer receive ifosfamide . - To document renal function nephrotoxicity one occasion 1 month 5 year completion ifosfamide treatment . - To determine relationship CYP3A5 genotype ifosfamide nephrotoxicity . Secondary - To compare measure glomerular filtration rate ( GFR ) ( use radioisotope clearance method ) calculate use Cole ( weight creatinine ) model . OUTLINE : This multicenter study . Nephrotoxicity assessment perform patient undergone prior assessment* . NOTE : *Nephrotoxicity assessment perform 1 month 5 year completion ifosfamide chemotherapy . All patient undergo single blood sample collection . DNA extract sample genotyped know functional polymorphism CYP3A5 . The technique restriction fragment length polymorphism ( RFLP ) use detect single nucleotide polymorphism CYP3A5 . DNA may obtain stored tumor sample patient result renal investigation available , blood available CYP3A5 genotyping .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Received ifosfamide age 21 part treatment cancer include , limited , follow : Ewing sarcoma Rhabdomyosarcoma Nonrhabdomyosarcoma soft tissue sarcoma No renal infiltration tumor stage illness May treat one follow clinical trial : EuroEwingIntergroupEE99 SIOPMMT95 Patients receive CEV chemotherapy ( carboplatin , epirubicin , vincristine ) strategy 952 953 eligible CCLGEPSSGNRSTS2005 CCLGEPSSGRMS2005 PATIENT CHARACTERISTICS : Clinically stable undergo renal investigation No preexist renal impairment ( glomerular tubular ) prior treatment ifosfamide No known nephrotoxicity nephrotoxic supportive treatment ( aminoglycosides , amphotericin , acyclovir , cyclosporine , tacrolimus ) major contributory cause renal damage PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered acute nonrenal toxicity last course chemotherapy No prior nephrotoxic chemotherapy ( e.g. , cisplatin , carboplatin , melphalan , highdose methotrexate ) No prior radiotherapy field include kidney No prior removal renal tissue No concurrent ifosfamide</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>chemotherapeutic agent toxicity</keyword>
	<keyword>localize Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>nonmetastatic childhood soft tissue sarcoma</keyword>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>metastatic childhood soft tissue sarcoma</keyword>
	<keyword>recurrent childhood soft tissue sarcoma</keyword>
	<keyword>previously treat childhood rhabdomyosarcoma</keyword>
	<keyword>recurrent childhood rhabdomyosarcoma</keyword>
</DOC>